| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | I-BET-762 | GDSC1000 | pan-cancer | AAC | 0.022 | 0.4 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | -0.026 | 0.4 |
| mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | -0.042 | 0.4 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | -0.037 | 0.4 |
| mRNA | phloretin | CTRPv2 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.026 | 0.4 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | -0.098 | 0.4 |